Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836858 + Decitabine in AML
NCT02632721Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of BI 836858 in acute myeloid leukemia (AML) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 941 days. Started Jun 2016; status: completed.
02
Drugs
BI 836858
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02632721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632721.